Histamine-2 (H2) antagonists can be safely removed from standard paclitaxel premedication regimens
Brit J Clinical Pharma - 2022 - Foreman - Histamine‐2 H2 antagonists can be safely removed from standard paclitaxel
File type: application/pdfDownload resource
BOPA encourages its members to share helpful documents that can benefit other members. BOPA respects the intellectual property of original authors and requires anyone who uses other members’ work to include an acknowledgment of, or reference to, the source in their version.
BOPA is not the author or owner of some of the documents published on our website. BOPA as a professional interest group will share documents via its website that are of interest to BOPA members, but has no responsibility for use of the documents and for any recommendations within the documents so members must use these at their discretion. BOPA cannot accept responsibility for any errors or omissions or for any consequences from application of information in the documents attached and make no warranty, expressed or implicit with respect to the contents of this webpage. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site or document(s) downloaded from it.
Posters and abstracts on the BOPA website remain the property of the authors and anyone wishing to reference or share this work must contact the authors directly. Abstracts subsequently published in JOPP follow copyright rules from JOPP.
25th BOPA Symposium 2022
7th to 9th October 2022 at The ACC Liverpool
Please click here to view the latest agenda.
CONFERENCE FEES (includes VAT)
Early-bird rate applies up until Monday 22nd August 2022